Welcome to our dedicated page for Barinthus Biotherapeutics plc news (Ticker: vacc), a resource for investors and traders seeking the latest updates and insights on Barinthus Biotherapeutics plc stock.
Barinthus Biotherapeutics (NASDAQ: BRNS) is a clinical-stage innovator developing T cell immunotherapies for chronic diseases and cancer. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory developments, and scientific breakthroughs.
Our curated collection features verified updates on Barinthus’ pipeline programs including VTP-300 for Hepatitis B and VTP-200 targeting HPV. Track progress across all development stages – from preclinical research to late-phase trials – with timely reports on study initiations, data readouts, and partnership announcements.
Key focus areas include updates on the company’s proprietary platforms like ChAdOx and MVA vector systems, financial position updates, and strategic collaborations. Recent highlights feature Phase 2 HBV trial developments and manufacturing scale-up initiatives.
Bookmark this page for structured access to Barinthus Biotherapeutics’ latest advancements in immune-guided therapies. All content is sourced from company filings and official communications to ensure reliability.
Vaccitech plc (NASDAQ: VACC) released its financial results for the year ending December 31, 2021, showcasing significant strides in its clinical pipeline. The company raised a total of $166.5 million from a Series B financing and its NASDAQ listing, with cash reserves now at $214.1 million, enough to sustain operations into 2024. Notable developments included the initiation of clinical trials for VTP-200 and VTP-300 targeting HPV and HBV, respectively. The net loss for 2021 was $50.9 million, reflecting increased R&D and administrative expenses. Upcoming milestones include further data presentations in mid-2022.
Vaccitech plc (NASDAQ: VACC) announced participation in a fireside chat at the Barclays Global Healthcare Conference on March 15, 2022, at 2:05 p.m. EDT, featuring CEO Bill Enright and CFO Georgy Egorov in Miami. The webcast will be available live and later as a replay on the company's website. Vaccitech focuses on developing immunotherapies for chronic infectious diseases and cancer using proprietary platforms, including modified viral vectors. The company co-invented a COVID-19 vaccine with the University of Oxford, licensed to AstraZeneca.
Vaccitech plc (Nasdaq: VACC) and its partners have begun the MAGE trial, marking a significant milestone in lung cancer treatment. The phase I/IIa trial is testing VTP-600, an immunotherapy administered to patients with non-small cell lung cancer (NSCLC), with initial dosing already completed for the first patient. The trial will involve about 86 participants, focusing on VTP-600’s safety and effectiveness alongside standard NSCLC treatments. If successful, VTP-600 may expand to other cancers like breast and bowel cancer, offering new hope for patients in critical need of better treatments.
Vaccitech plc has announced a virtual Key Opinion Leader (KOL) event for its VTP-300 product, scheduled for January 25, 2022, at 8:30 a.m. EST. This event will focus on VTP-300's role in chronic hepatitis B (CHB) treatment and the surrounding therapeutic landscape. Renowned experts, including Dr. Kaushik Agarwal and Dr. Henry L. Y. Chan, will be featured speakers. Interested parties can access the live webcast via the company's Investor Relations page.
Vaccitech (NASDAQ: VACC) has announced the acquisition of Avidea Technologies for $40 million, comprising $12.5 million in cash and $27.5 million in Vaccitech shares. This deal aims to enhance Vaccitech's position in the immunotherapy and vaccine markets, particularly through Avidea's SNAPvax™ platform, which allows for improved T cell responses. The acquisition is expected to broaden Vaccitech's therapeutic pipeline, with potential IND filings within 12 months. The merger brings together a strong R&D team from leading institutions, reinforcing Vaccitech's operational presence in the U.S.
The interim analysis of the HBV002 study, involving 27 chronic Hepatitis B patients, highlighted significant decreases in surface antigen (HBsAg) levels, particularly in those receiving low-dose nivolumab with VTP-300. Notably, Group 3 showed a mean HBsAg reduction of -1.04 with 3 out of 6 patients achieving notable decreases. The study will focus on Groups 2 and 3 for further enrollment and analysis in 2022, with expectations for forthcoming data on HBsAg levels. Vaccitech confirmed that VTP-300 has shown promising immunogenicity and safety profiles in patients, emphasizing potential advancements in chronic HBV treatment.
Vaccitech plc (NASDAQ: VACC) announced participation in the 33rd Annual Virtual Piper Sandler Healthcare Conference from November 30 to December 2, 2021. CEO Bill Enright and CFO Georgy Egorov will engage in a pre-recorded fireside chat, available on-demand starting November 22, 2021. Vaccitech specializes in developing immunotherapeutics and vaccines for infectious diseases and cancer, including a co-invented COVID-19 vaccine with the University of Oxford, licensed to AstraZeneca. The company's proprietary platforms promise enhanced immunological responses.
Vaccitech plc (NASDAQ: VACC) announced interim results from clinical trials HBV001 and HBV002, demonstrating that the heterologous prime-boost combination of ChAdOx1-HBV and MVA-HBV (VTP-300) elicited strong T cell responses in chronic Hepatitis B patients. Both studies reported good tolerability, without serious adverse events. The T cells were cross-reactive to major HBV genotypes C and D, suggesting VTP-300's potential for a functional cure. These findings were presented at the AASLD The Liver Meeting®.
Vaccitech plc (NASDAQ: VACC) reported its Q3 2021 financial results, ending September 30, 2021. The company continues to advance its immunotherapeutics and vaccines, with significant developments in its MERS vaccine program and a collaboration with Arbutus Biopharma for hepatitis B treatment. Financial highlights include a cash position of $233.9 million, a net loss of $4.6 million, and increased R&D expenses of $4.4 million. The company anticipates funding operations through the first half of 2024, supported by a successful Series B financing and IPO that raised over $278 million combined.
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company, announced that CEO Bill Enright will present at the Jefferies London Healthcare Conference on November 17, 2021. The presentation will be in person and as a webcast fireside chat, scheduled for 8 a.m. GMT (3 a.m. EST). An audio webcast will be accessible through the Events section of the Vaccitech website, with archived replays available post-event. Vaccitech focuses on developing immunotherapeutics and vaccines to treat infectious diseases and cancer.
